Based on recent findings, in the absence of family history suggesting any other genetic conditions, at least the TP53 gene analysis should be offered to all ACC patients.[7,8] Furthermore, the efficacy of ACC surveillance strategy among children found to have a TP53 mutation was proven with better outcome and survival.[14] Thus, the identification of an unsuspected germline TP53 mutation may entail a clinical surveillance protocol for the detection of asymptomatic nonadrenal neoplasms in individuals with germline TP53 mutations.[15]. This evidence concerns the gene TP53 and adrenal cortex carcinoma.